Cardiol Therapeutics (TSE:CRDL) Stock Price Up 1.6%

Shares of Cardiol Therapeutics Inc. (TSE:CRDL) traded up 1.6% on Tuesday . The company traded as high as C$3.10 and last traded at C$3.09. 75,371 shares changed hands during trading, a decline of 50% from the average session volume of 150,386 shares. The stock had previously closed at C$3.04.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating on shares of Cardiol Therapeutics in a research report on Monday, April 22nd.

Cardiol Therapeutics Trading Up 2.0 %

The stock has a 50-day moving average price of C$3.05 and a two-hundred day moving average price of C$2.46. The stock has a market capitalization of C$213.90 million, a PE ratio of -6.60 and a beta of 0.68. The company has a debt-to-equity ratio of 0.83, a quick ratio of 6.84 and a current ratio of 2.81.

Insider Activity at Cardiol Therapeutics

In other Cardiol Therapeutics news, Director David Elsley bought 50,000 shares of the firm’s stock in a transaction that occurred on Monday, June 24th. The shares were bought at an average price of C$2.77 per share, with a total value of C$138,490.00. 4.42% of the stock is owned by corporate insiders.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.